Closed Research Teams

 

Recent submissions

  • Large-scale Sequencing of Testicular Germ Cell Tumour (TGCT) Cases Excludes Major TGCT Predisposition Gene. 

    Litchfield, K; Loveday, C; Levy, M; Dudakia, D; Rapley, E; Nsengimana, J; Bishop, DT; Reid, A; Huddart, R; Broderick, P; Houlston, RS; Turnbull, C (2018-02-09)
    Testicular germ cell tumour (TGCT), the most common cancer in young men, has a significant heritable basis that has long raised questions as to the existence of underlying major high-penetrance susceptibility gene(s). To ...

  • Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data. 

    Camacho, N; Van Loo, P; Edwards, S; Kay, JD; Matthews, L; Haase, K; Clark, J; Dennis, N; Thomas, S; Kremeyer, B; Zamora, J; Butler, AP; Gundem, G; Merson, S; Luxton, H; Hawkins, S; Ghori, M; Marsden, L; Lambert, A; Karaszi, K; Pelvender, G; Massie, CE; Kote-Jarai, Z; Raine, K; Jones, D; Howat, WJ; Hazell, S; Livni, N; Fisher, C; Ogden, C; Kumar, P; Thompson, A; Nicol, D; Mayer, E; Dudderidge, T; Yu, Y; Zhang, H; Shah, NC; Gnanapragasam, VJ; CRUK-ICGC Prostate Group; Isaacs, W; Visakorpi, T; Hamdy, F; Berney, D; Verrill, C; Warren, AY; Wedge, DC; Lynch, AG; Foster, CS; Lu, YJ; Bova, GS; Whitaker, HC; McDermott, U; Neal, DE; Eeles, R; Cooper, CS; Brewer, DS (2017-09)
    A variety of models have been proposed to explain regions of recurrent somatic copy number alteration (SCNA) in human cancer. Our study employs Whole Genome DNA Sequence (WGS) data from tumor samples (n = 103) to comprehensively ...

  • Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor. 

    Whittaker, SR; Barlow, C; Martin, MP; Mancusi, C; Wagner, S; Self, A; Barrie, E; Te Poele, R; Sharp, S; Brown, N; Wilson, S; Jackson, W; Fischer, PM; Clarke, PA; Walton, MI; McDonald, E; Blagg, J; Noble, M; Garrett, MD; Workman, P (2018-03)
    Deregulation of the cyclin-dependent kinases (CDKs) has been implicated in the pathogenesis of multiple cancer types. Consequently, CDKs have garnered intense interest as therapeutic targets for the treatment of cancer. ...

  • Large-scale genotyping identifies 41 new loci associated with breast cancer risk. 

    Michailidou, K; Hall, P; Gonzalez-Neira, A; Ghoussaini, M; Dennis, J; Milne, RL; Schmidt, MK; Chang-Claude, J; Bojesen, SE; Bolla, MK; Wang, Q; Dicks, E; Lee, A; Turnbull, C; Rahman, N; Fletcher, O; Peto, J; Gibson, L; Dos Santos Silva, I; Nevanlinna, H; Muranen, TA; Aittomäki, K; Blomqvist, C; Czene, K; Irwanto, A; Liu, J; Waisfisz, Q; Meijers-Heijboer, H; Adank, M; van der Luijt, RB; Hein, R; Dahmen, N; Beckman, L; Meindl, A; Schmutzler, RK; Müller-Myhsok, B; Lichtner, P; Hopper, JL; Southey, MC; Makalic, E; Schmidt, DF; Uitterlinden, AG; Hofman, A; Hunter, DJ; Chanock, SJ; Vincent, D; Bacot, F; Tessier, DC; Canisius, S; Wessels, LF; Haiman, CA; Shah, M; Luben, R; Brown, J; Luccarini, C; Schoof, N; Humphreys, K; Li, J; Nordestgaard, BG; Nielsen, SF; Flyger, H; Couch, FJ; Wang, X; Vachon, C; Stevens, KN; Lambrechts, D; Moisse, M; Paridaens, R; Christiaens, MR; Rudolph, A; Nickels, S; Flesch-Janys, D; Johnson, N; Aitken, Z; Aaltonen, K; Heikkinen, T; Broeks, A; Veer, LJ; van der Schoot, CE; Guénel, P; Truong, T; Laurent-Puig, P; Menegaux, F; Marme, F; Schneeweiss, A; Sohn, C; Burwinkel, B; Zamora, MP; Perez, JI; Pita, G; Alonso, MR; Cox, A; Brock, IW; Cross, SS; Reed, MW; Sawyer, EJ; Tomlinson, I; Kerin, MJ; Miller, N; Henderson, BE; Schumacher, F; Le Marchand, L; Andrulis, IL; Knight, JA; Glendon, G; Mulligan, AM; Lindblom, A; Margolin, S; Hooning, MJ; Hollestelle, A; van den Ouweland, AM; Jager, A; Bui, QM; Stone, J; Dite, GS; Apicella, C; Tsimiklis, H; Giles, GG; Severi, G; Baglietto, L; Fasching, PA; Haeberle, L; Ekici, AB; Beckmann, MW; Brenner, H; Müller, H; Arndt, V; Stegmaier, C; Swerdlow, A; Ashworth, A; Orr, N; Jones, M; Figueroa, J; Lissowska, J; Brinton, L; Goldberg, MS; Labrèche, F; Dumont, M; Winqvist, R; Pylkäs, K; Jukkola-Vuorinen, A; Grip, M; Brauch, H; Hamann, U; Brüning, T; Radice, P; Peterlongo, P; Manoukian, S; Bonanni, B; Devilee, P; Tollenaar, RA; Seynaeve, C; van Asperen, CJ; Jakubowska, A; Lubinski, J; Jaworska, K; Durda, K; Mannermaa, A; Kataja, V; Kosma, VM; Hartikainen, JM; Bogdanova, NV; Antonenkova, NN; Dörk, T; Kristensen, VN; Anton-Culver, H; Slager, S; Toland, AE; Edge, S; Fostira, F; Kang, D; Yoo, KY; Noh, DY; Matsuo, K; Ito, H; Iwata, H; Sueta, A; Wu, AH; Tseng, CC; Van Den Berg, D; Stram, DO; Shu, XO; Lu, W; Gao, YT; Cai, H; Teo, SH; Yip, CH; Phuah, SY; Cornes, BK; Hartman, M; Miao, H; Lim, WY; Sng, JH; Muir, K; Lophatananon, A; Stewart-Brown, S; Siriwanarangsan, P; Shen, CY; Hsiung, CN; Wu, PE; Ding, SL; Sangrajrang, S; Gaborieau, V; Brennan, P; McKay, J; Blot, WJ; Signorello, LB; Cai, Q; Zheng, W; Deming-Halverson, S; Shrubsole, M; Long, J; Simard, J; Garcia-Closas, M; Pharoah, PD; Chenevix-Trench, G; Dunning, AM; Benitez, J; Easton, DF (2013-04)
    Breast cancer is the most common cancer among women. Common variants at 27 loci have been identified as associated with susceptibility to breast cancer, and these account for ∼9% of the familial risk of the disease. We ...

  • No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. 

    Hollestelle, A; van der Baan, FH; Berchuck, A; Johnatty, SE; Aben, KK; Agnarsson, BA; Aittomäki, K; Alducci, E; Andrulis, IL; Anton-Culver, H; Antonenkova, NN; Antoniou, AC; Apicella, C; Arndt, V; Arnold, N; Arun, BK; Arver, B; Ashworth, A; Baglietto, L; Balleine, R; Bandera, EV; Barrowdale, D; Bean, YT; Beckmann, L; Beckmann, MW; Benitez, J; Berger, A; Berger, R; Beuselinck, B; Bisogna, M; Bjorge, L; Blomqvist, C; Bogdanova, NV; Bojesen, A; Bojesen, SE; Bolla, MK; Bonanni, B; Brand, JS; Brauch, H; Brenner, H; Brinton, L; Brooks-Wilson, A; Bruinsma, F; Brunet, J; Brüning, T; Budzilowska, A; Bunker, CH; Burwinkel, B; Butzow, R; Buys, SS; Caligo, MA; Campbell, I; Carter, J; Chang-Claude, J; Chanock, SJ; Claes, KB; Collée, JM; Cook, LS; Couch, FJ; Cox, A; Cramer, D; Cross, SS; Cunningham, JM; Cybulski, C; Czene, K; Damiola, F; Dansonka-Mieszkowska, A; Darabi, H; de la Hoya, M; deFazio, A; Dennis, J; Devilee, P; Dicks, EM; Diez, O; Doherty, JA; Domchek, SM; Dorfling, CM; Dörk, T; Silva, IS; du Bois, A; Dumont, M; Dunning, AM; Duran, M; Easton, DF; Eccles, D; Edwards, RP; Ehrencrona, H; Ejlertsen, B; Ekici, AB; Ellis, SD; Engel, C; Eriksson, M; Fasching, PA; Feliubadalo, L; Figueroa, J; Flesch-Janys, D; Fletcher, O; Fontaine, A; Fortuzzi, S; Fostira, F; Fridley, BL; Friebel, T; Friedman, E; Friel, G; Frost, D; Garber, J; García-Closas, M; Gayther, SA; Gentry-Maharaj, A; Gerdes, AM; Giles, GG; Glasspool, R; Glendon, G; Godwin, AK; Goodman, MT; Gore, M; Greene, MH; Grip, M; Gronwald, J; Gschwantler Kaulich, D; Guénel, P; Guzman, SR; Haeberle, L; Haiman, CA; Hall, P; Halverson, SL; Hamann, U; Hansen, TV; Harter, P; Hartikainen, JM; Healey, S; Hein, A; Heitz, F; Henderson, BE; Herzog, J; T Hildebrandt, MA; Høgdall, CK; Høgdall, E; Hogervorst, FB; Hopper, JL; Humphreys, K; Huzarski, T; Imyanitov, EN; Isaacs, C; Jakubowska, A; Janavicius, R; Jaworska, K; Jensen, A; Jensen, UB; Johnson, N; Jukkola-Vuorinen, A; Kabisch, M; Karlan, BY; Kataja, V; Kauff, N; Kelemen, LE; Kerin, MJ; Kiemeney, LA; Kjaer, SK; Knight, JA; Knol-Bout, JP; Konstantopoulou, I; Kosma, VM; Krakstad, C; Kristensen, V; Kuchenbaecker, KB; Kupryjanczyk, J; Laitman, Y; Lambrechts, D; Lambrechts, S; Larson, MC; Lasa, A; Laurent-Puig, P; Lazaro, C; Le, ND; Le Marchand, L; Leminen, A; Lester, J; Levine, DA; Li, J; Liang, D; Lindblom, A; Lindor, N; Lissowska, J; Long, J; Lu, KH; Lubinski, J; Lundvall, L; Lurie, G; Mai, PL; Mannermaa, A; Margolin, S; Mariette, F; Marme, F; Martens, JW; Massuger, LF; Maugard, C; Mazoyer, S; McGuffog, L; McGuire, V; McLean, C; McNeish, I; Meindl, A; Menegaux, F; Menéndez, P; Menkiszak, J; Menon, U; Mensenkamp, AR; Miller, N; Milne, RL; Modugno, F; Montagna, M; Moysich, KB; Müller, H; Mulligan, AM; Muranen, TA; Narod, SA; Nathanson, KL; Ness, RB; Neuhausen, SL; Nevanlinna, H; Neven, P; Nielsen, FC; Nielsen, SF; Nordestgaard, BG; Nussbaum, RL; Odunsi, K; Offit, K; Olah, E; Olopade, OI; Olson, JE; Olson, SH; Oosterwijk, JC; Orlow, I; Orr, N; Orsulic, S; Osorio, A; Ottini, L; Paul, J; Pearce, CL; Pedersen, IS; Peissel, B; Pejovic, T; Pelttari, LM; Perkins, J; Permuth-Wey, J; Peterlongo, P; Peto, J; Phelan, CM; Phillips, KA; Piedmonte, M; Pike, MC; Platte, R; Plisiecka-Halasa, J; Poole, EM; Poppe, B; Pylkäs, K; Radice, P; Ramus, SJ; Rebbeck, TR; Reed, MW; Rennert, G; Risch, HA; Robson, M; Rodriguez, GC; Romero, A; Rossing, MA; Rothstein, JH; Rudolph, A; Runnebaum, I; Salani, R; Salvesen, HB; Sawyer, EJ; Schildkraut, JM; Schmidt, MK; Schmutzler, RK; Schneeweiss, A; Schoemaker, MJ; Schrauder, MG; Schumacher, F; Schwaab, I; Scuvera, G; Sellers, TA; Severi, G; Seynaeve, CM; Shah, M; Shrubsole, M; Siddiqui, N; Sieh, W; Simard, J; Singer, CF; Sinilnikova, OM; Smeets, D; Sohn, C; Soller, M; Song, H; Soucy, P; Southey, MC; Stegmaier, C; Stoppa-Lyonnet, D; Sucheston, L; Swerdlow, A; Tangen, IL; Tea, MK; Teixeira, MR; Terry, KL; Terry, MB; Thomassen, M; Thompson, PJ; Tihomirova, L; Tischkowitz, M; Toland, AE; Tollenaar, RA; Tomlinson, I; Torres, D; Truong, T; Tsimiklis, H; Tung, N; Tworoger, SS; Tyrer, JP; Vachon, CM; Van 't Veer, LJ; van Altena, AM; Van Asperen, CJ; van den Berg, D; van den Ouweland, AM; van Doorn, HC; Van Nieuwenhuysen, E; van Rensburg, EJ; Vergote, I; Verhoef, S; Vierkant, RA; Vijai, J; Vitonis, AF; von Wachenfeldt, A; Walsh, C; Wang, Q; Wang-Gohrke, S; Wappenschmidt, B; Weischer, M; Weitzel, JN; Weltens, C; Wentzensen, N; Whittemore, AS; Wilkens, LR; Winqvist, R; Wu, AH; Wu, X; Yang, HP; Zaffaroni, D; Pilar Zamora, M; Zheng, W; Ziogas, A; Chenevix-Trench, G; Pharoah, PD; Rookus, MA; Hooning, MJ; Goode, EL (2016-05)
    Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well ...

  • Systematic evaluation of quantotypic peptides for targeted analysis of the human kinome. 

    Worboys, JD; Sinclair, J; Yuan, Y; Jørgensen, C (2014-10)
    In targeted proteomics it is critical that peptides are not only proteotypic but also accurately represent the level of the protein (quantotypic). Numerous approaches are used to identify proteotypic peptides, but quantotypic ...

  • Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma. 

    Giles, SL; Messiou, C; Collins, DJ; Morgan, VA; Simpkin, CJ; West, S; Davies, FE; Morgan, GJ; deSouza, NM (2014-06)
    To determine the feasibility of whole-body diffusion-weighted (DW) magnetic resonance (MR) imaging for assessment of treatment response in myeloma.This prospective single-institution study was HIPAA-compliant with local ...

  • Reproducible automated phosphopeptide enrichment using magnetic TiO2 and Ti-IMAC. 

    Tape, CJ; Worboys, JD; Sinclair, J; Gourlay, R; Vogt, J; McMahon, KM; Trost, M; Lauffenburger, DA; Lamont, DJ; Jørgensen, C (2014-10-02)
    Reproducible, comprehensive phosphopeptide enrichment is essential for studying phosphorylation-regulated processes. Here, we describe the application of hyper-porous magnetic TiO2 and Ti-IMAC microspheres for uniform ...

  • Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. 

    Frentzas, S; Simoneau, E; Bridgeman, VL; Vermeulen, PB; Foo, S; Kostaras, E; Nathan, M; Wotherspoon, A; Gao, Z-H; Shi, Y; Van den Eynden, G; Daley, F; Peckitt, C; Tan, X; Salman, A; Lazaris, A; Gazinska, P; Berg, TJ; Eltahir, Z; Ritsma, L; Van Rheenen, J; Khashper, A; Brown, G; Nystrom, H; Sund, M; Van Laere, S; Loyer, E; Dirix, L; Cunningham, D; Metrakos, P; Reynolds, AR
    The efficacy of angiogenesis inhibitors in cancer is limited by resistance mechanisms that are poorly understood. Notably, instead of through the induction of angiogenesis, tumor vascularization can occur through the ...

  • Imaging biomarker roadmap for cancer studies. 

    O'Connor, JPB; Aboagye, EO; Adams, JE; Aerts, HJWL; Barrington, SF; Beer, AJ; Boellaard, R; Bohndiek, SE; Brady, M; Brown, G; Buckley, DL; Chenevert, TL; Clarke, LP; Collette, S; Cook, GJ; deSouza, NM; Dickson, JC; Dive, C; Evelhoch, JL; Faivre-Finn, C; Gallagher, FA; Gilbert, FJ; Gillies, RJ; Goh, V; Griffiths, JR; Groves, AM; Halligan, S; Harris, AL; Hawkes, DJ; Hoekstra, OS; Huang, EP; Hutton, BF; Jackson, EF; Jayson, GC; Jones, A; Koh, D-M; Lacombe, D; Lambin, P; Lassau, N; Leach, MO; Lee, T-Y; Leen, EL; Lewis, JS; Liu, Y; Lythgoe, MF; Manoharan, P; Maxwell, RJ; Miles, KA; Morgan, B; Morris, S; Ng, T; Padhani, AR; Parker, GJM; Partridge, M; Pathak, AP; Peet, AC; Punwani, S; Reynolds, AR; Robinson, SP; Shankar, LK; Sharma, RA; Soloviev, D; Stroobants, S; Sullivan, DC; Taylor, SA; Tofts, PS; Tozer, GM; van Herk, M; Walker-Samuel, S; Wason, J; Williams, KJ; Workman, P; Yankeelov, TE; Brindle, KM; McShane, LM; Jackson, A; Waterton, JC
    Imaging biomarkers (IBs) are integral to the routine management of patients with cancer. IBs used daily in oncology include clinical TNM stage, objective response and left ventricular ejection fraction. Other CT, MRI, PET ...

  • Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. 

    Bridgeman, VL; Vermeulen, PB; Foo, S; Bilecz, A; Daley, F; Kostaras, E; Nathan, MR; Wan, E; Frentzas, S; Schweiger, T; Hegedus, B; Hoetzenecker, K; Renyi-Vamos, F; Kuczynski, EA; Vasudev, NS; Larkin, J; Gore, M; Dvorak, HF; Paku, S; Kerbel, RS; Dome, B; Reynolds, AR (2017-02)
    Anti-angiogenic therapies have shown limited efficacy in the clinical management of metastatic disease, including lung metastases. Moreover, the mechanisms via which tumours resist anti-angiogenic therapies are poorly ...

  • ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. 

    Williamson, CT; Miller, R; Pemberton, HN; Jones, SE; Campbell, J; Konde, A; Badham, N; Rafiq, R; Brough, R; Gulati, A; Ryan, CJ; Francis, J; Vermulen, PB; Reynolds, AR; Reaper, PM; Pollard, JR; Ashworth, A; Lord, CJ (2016-12-13)
    Identifying genetic biomarkers of synthetic lethal drug sensitivity effects provides one approach to the development of targeted cancer therapies. Mutations in ARID1A represent one of the most common molecular alterations ...

  • Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation. 

    Tape, CJ; Ling, S; Dimitriadi, M; McMahon, KM; Worboys, JD; Leong, HS; Norrie, IC; Miller, CJ; Poulogiannis, G; Lauffenburger, DA; Jørgensen, C (2016-06)

  • Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation. 

    Tape, CJ; Ling, S; Dimitriadi, M; McMahon, KM; Worboys, JD; Leong, HS; Norrie, IC; Miller, CJ; Poulogiannis, G; Lauffenburger, DA; Jørgensen, C (2016-05)
    Oncogenic mutations regulate signaling within both tumor cells and adjacent stromal cells. Here, we show that oncogenic KRAS (KRAS(G12D)) also regulates tumor cell signaling via stromal cells. By combining cell-specific ...

  • Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma. 

    Kuczynski, EA; Yin, M; Bar-Zion, A; Lee, CR; Butz, H; Man, S; Daley, F; Vermeulen, PB; Yousef, GM; Foster, FS; Reynolds, AR; Kerbel, RS (2016-08)
    The anti-angiogenic Sorafenib is the only approved systemic therapy for advanced hepatocellular carcinoma (HCC). However, acquired resistance limits its efficacy. An emerging theory to explain intrinsic resistance to other ...

  • Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. 

    Johnson, N; Dudbridge, F; Orr, N; Gibson, L; Jones, ME; Schoemaker, MJ; Folkerd, EJ; Haynes, BP; Hopper, JL; Southey, MC; Dite, GS; Apicella, C; Schmidt, MK; Broeks, A; Van't Veer, LJ; Atsma, F; Muir, K; Lophatananon, A; Fasching, PA; Beckmann, MW; Ekici, AB; Renner, SP; Sawyer, E; Tomlinson, I; Kerin, M; Miller, N; Burwinkel, B; Marme, F; Schneeweiss, A; Sohn, C; Guénel, P; Truong, T; Cordina, E; Menegaux, F; Bojesen, SE; Nordestgaard, BG; Flyger, H; Milne, R; Zamora, MP; Arias Perez, JI; Benitez, J; Bernstein, L; Anton-Culver, H; Ziogas, A; Clarke Dur, C; Brenner, H; Müller, H; Arndt, V; Dieffenbach, AK; Meindl, A; Heil, J; Bartram, CR; Schmutzler, RK; Brauch, H; Justenhoven, C; Ko, YD; Nevanlinna, H; Muranen, TA; Aittomäki, K; Blomqvist, C; Matsuo, K; Dörk, T; Bogdanova, NV; Antonenkova, NN; Lindblom, A; Mannermaa, A; Kataja, V; Kosma, VM; Hartikainen, JM; Chenevix-Trench, G; Beesley, J; Wu, AH; Van den Berg, D; Tseng, CC; Lambrechts, D; Smeets, D; Neven, P; Wildiers, H; Chang-Claude, J; Rudolph, A; Nickels, S; Flesch-Janys, D; Radice, P; Peterlongo, P; Bonanni, B; Pensotti, V; Couch, FJ; Olson, JE; Wang, X; Fredericksen, Z; Pankratz, VS; Giles, GG; Severi, G; Baglietto, L; Haiman, C; Simard, J; Goldberg, MS; Labrèche, F; Dumont, M; Soucy, P; Teo, S; Yip, CH; Phuah, SY; Cornes, BK; Kristensen, VN; Grenaker Alnæs, G; Børresen-Dale, AL; Zheng, W; Winqvist, R; Pylkäs, K; Jukkola-Vuorinen, A; Grip, M; Andrulis, IL; Knight, JA; Glendon, G; Mulligan, AM; Devillee, P; Figueroa, J; Chanock, SJ; Lissowska, J; Sherman, ME; Hall, P; Schoof, N; Hooning, M; Hollestelle, A; Oldenburg, RA; Tilanus-Linthorst, M; Liu, J; Cox, A; Brock, IW; Reed, MW; Cross, SS; Blot, W; Signorello, LB; Pharoah, PD; Dunning, AM; Shah, M; Kang, D; Noh, DY; Park, SK; Choi, JY; Hartman, M; Miao, H; Lim, WY; Tang, A; Hamann, U; Försti, A; Rüdiger, T; Ulmer, HU; Jakubowska, A; Lubinski, J; Jaworska-Bieniek, K; Durda, K; Sangrajrang, S; Gaborieau, V; Brennan, P; McKay, J; Slager, S; Toland, AE; Vachon, C; Yannoukakos, D; Shen, CY; Yu, JC; Huang, CS; Hou, MF; González-Neira, A; Tessier, DC; Vincent, D; Bacot, F; Luccarini, C; Dennis, J; Michailidou, K; Bolla, MK; Wang, J; Easton, DF; García-Closas, M; Dowsett, M; Ashworth, A; Swerdlow, AJ; Peto, J; dos Santos Silva, I; Fletcher, O (2014-01)
    We have previously shown that a tag single nucleotide polymorphism (rs10235235), which maps to the CYP3A locus (7q22.1), was associated with a reduction in premenopausal urinary estrone glucuronide levels and a modest ...

  • Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma. 

    George, SL; Falzone, N; Chittenden, S; Kirk, SJ; Lancaster, D; Vaidya, SJ; Mandeville, H; Saran, F; Pearson, AD; Du, Y; Meller, ST; Denis-Bacelar, AM; Flux, GD (2016-05)
    Iodine-131-labelled meta-iodobenzylguanidine (I-mIBG) therapy is an established treatment modality for relapsed/refractory neuroblastoma, most frequently administered according to fixed or weight-based criteria. We evaluate ...